{"id":3241,"date":"2020-03-19T15:52:20","date_gmt":"2020-03-19T14:52:20","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/pitch-day-investoren-treffen-sich-im-izb\/"},"modified":"2020-07-14T12:38:38","modified_gmt":"2020-07-14T10:38:38","slug":"pitch-day-investoren-treffen-sich-im-izb","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/pitch-day-investoren-treffen-sich-im-izb\/","title":{"rendered":"Pitch Day: Investors meet in the IZB"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

PiTch Day: investors meet in the IZB<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]July 2017[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”3222″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”](f.l.t.r.) Dr. Georg Ried, Bayern Kapital, Dr. Karin Kleinhans, LSP, Philipp Hermannsd\u00f6rfer, BayStartUp, Dr. Peter Hanns Zobel, F\u00f6rdergesellschaft IZB mbH, Dr. Mathias Falcenberg, Forbion, Dr. Timothy Luker, Eli Lilly,Dr. Matthias Kromayer, MIG AG, Dr. Kreske Nickelsen, Coparion, Dr. Dirk Vocke, Merck KGaA, Dr. Christian Jung, Wellington Partners, Dr. Marianne Mertens, High-Tech Gr\u00fcnderfonds, Prof. Dr. Stefan Jaroch, Bayer AG, Dr. Klaus Mendla, Boehringer Ingelheim[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Eight science teams give presen\u00adtations at 3rd Munich Life Science Pitch Day at the IZB. Start-ups profit from being in close contact with the venture capital scene. <\/strong><\/p>\n

Auly 6 2017 \u2013 High-Tech Gr\u00fcnderfonds, Bayer Pharma AG, Merck KGaA and the Innovation and Start-up Center for Biotechnology (IZB) hosted the 3rd Munich Life Science Pitch Day at the IZB. Eight start-up teams had the opportunity to present their pioneering projects \u00adin front of 15 renowned venture capital and pharmaceutical companies. Among the prominent names taking \u00adpart were MIG Fonds, Forbion Capital Partners, LSP Venture Capital, TVM Capital, Gimv, Biomed Partners, Bayern Kapital, Coparion, Vesalius Biocapital, Wellington Partners, Eli Lilly and Boehringer Ingelheim. The investors were impressed by the innovative ideas of the science teams as well as the consistently high level of quality of the presentations given. Dr. Marianne Mertens, Investment Manager in the Life Sciences team at High-Tech Gr\u00fcnderfonds, and Dr. Matthias Kromayer, Executive Board member at MIG AG, presided over the event.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner][vc_single_image image=”3224″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription” el_id=”special-high”]Dr. Matthias Kromayer, CEO, MIG AG,
\nProf. Dr. Armin Giese,\u00a0 Center for Neuropathology and Prion Research of the LMU[\/vc_column_text][vc_single_image image=”3230″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription” el_id=”special-high”](f.l.t.r.) Dr. Marianne Mertens, Investment Manager, High-Tech Gr\u00fcnderfonds, Dr. Alexandra Goll, Senior Advisor, TVM Capital[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]”We are delighted that through the Life Science Pitch Day, we have created a platform that supports start-ups in finding suitable investors. Furthermore, in hosting the Asset Lounge for the first time we are looking to bring together entrepreneurs and technologies with the aim of implementing innovative ideas and developments. Together with strong partners from the venture capital sector and industry, we are hoping to put companies with high potential on the right track and lead them to success,\u201d says Dr. Marianne Mertens.
\nProf. Dr. Stefan Jaroch, Head of External Innovation Technologies at Bayer Pharma AG, is a partner of the event for the third time: \u201cAt the Pitch Day, we are seeking to initiate a dialogue with young entrepreneurs and investors in the life sciences sector. This complements our activities as an investor in High-Tech Gr\u00fcnderfonds and in managing the Co-Laborator incubators in San Francisco and Berlin. We are looking to foster an exchange of ideas while offering our expertise,\u201d explains Jaroch. \uf04d \uf04d<\/p>\n

<\/div>\n

[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner][vc_single_image image=”3232″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Peter Hanns Zobel, IZB mbH,
\nFlorian Hahn, MdB[\/vc_column_text][vc_single_image image=”3234″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Klaus Mendla, Global Head, CNS Business Development and Licensing, Boehringer Ingelheim [\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1594722990964{margin-bottom: 30px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\n
\u201cEli Lilly are looking to discover and partner with the best biomedical innovations at an increasingly early stage and events like this are very helpful in realising these goals.\u201c<\/h6>\n<\/blockquote>\n

Dr. Tim Luker, Senior Director,
\nEmerging Technology & Innovation, Eli Lilly<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n